Unknown

Dataset Information

0

517. Subcutaneous Sarilumab for the Treatment of Hospitalized patients with Moderate to Severe COVID19 Disease: A Pragmatic, Embedded, Multi-Center Randomized Clinical Trial

ABSTRACT:

SUBMITTER: Branch-Elliman W 

PROVIDER: S-EPMC8690689 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial.
| S-EPMC8880885 | biostudies-literature
Unknown Subcutaneous IL-6 Inhibitor Sarilumab vs. Standard Care in Hospitalized Patients With Moderate-To-Severe COVID-19: An Open Label Randomized Clinical Trial.
| S-EPMC8904894 | biostudies-literature
Unknown Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial.
| S-EPMC7480631 | biostudies-literature
Unknown Subcutaneous Sarilumab in Patients With Rheumatoid Arthritis who Previously Received Subcutaneous Sarilumab or Intravenous Tocilizumab: An Open-Label Extension of a Randomized Clinical Trial.
| S-EPMC7672306 | biostudies-literature
Unknown Infections in Patients Receiving Subcutaneous Biological Treatments for Moderate to Severe Psoriasis.
| S-EPMC4883222 | biostudies-literature
Unknown Usability and Patient Preference Phase 3 Study of the Sarilumab Pen in Patients with Active Moderate-to-Severe Rheumatoid Arthritis.
| S-EPMC5935610 | biostudies-literature
Unknown Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial.
| S-EPMC8598187 | biostudies-literature
Unknown Sarilumab use in severe SARS-CoV-2 pneumonia.
| S-EPMC7531933 | biostudies-literature
Unknown Umifenovir in hospitalized moderate to severe COVID-19 patients: A randomized clinical trial.
| S-EPMC8270750 | biostudies-literature
Unknown Subcutaneous Biological Treatments for Moderate to Severe Psoriasis: Interpreting Safety Data by Network Meta-Analysis.
| S-EPMC4883196 | biostudies-literature